The CDEC has recommended that riociguat be listed for the management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH, World Health Organization [WHO] Group 4) or persistent or recurrent CTEPH after surgical treatment in adult patients (≥ 18 years of age) with WHO Functional Class II or III pulmonary hypertension if the following conditions are met: 

• Riociguat should be prescribed by a clinician with experience in the diagnosis and treatment of CTEPH

• A substantial reduction in price is required

For more details, go to: http://www.cadth.ca/media/cdr/complete/SR0353_complete_Adempas_Jul-21-14.pdf